| Name | Levetiracetam |
| Description | Levetiracetam (SIB-S1) is a relatively unique anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Levetiracetam has been linked to rare instances of serum aminotransferase and alkaline phosphatase elevations during treatment and to rare cases of clinically apparent drug induced liver disease. |
| Kinase Assay | EDTA plasma (20 μL) is diluted with 30 μL of DPP-4 assay buffer (100 mM Tris and 100 mM NaCl, adjusted to pH 7.8 with HCl) and mixed with 50 μL of H-Ala-Pro-7-amido-4-trifluoromethylcoumarin. The 200 mM stock solution in dimethylformamide is diluted 1:1000 with water to yield a final concentration of 100 μM. The plate is incubated at room temperature for 10 min, and fluorescence in the wells is determined by using a Victor 1420 Multilabel Counter at an excitation wavelength of 405 nm and an emission wavelength of 535 nm. For the detection of DPP-4 activity in wound lysates, 100 μg of protein from the respective wound lysates are used instead of 20 μL of plasma. Active GLP-1 is also detected from 100 μg of respective wound tissue samples and analyzed by using the Mouse/Rat Total Active GLP-1 Assay Kit. |
| In vitro | In a cellular assay, CNX-774 targeted residue Cys-481, the ATP-binding site of BTK, thereby inhibiting its activity (IC50: 1-10 nM). |
| In vivo | In a cellular assay, CNX-774 targeted residue Cys-481, the ATP-binding site of BTK, thereby inhibiting its activity (IC50: 1-10 nM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (293.75 mM)
H2O : 17 mg/mL (100 mM)
|
| Keywords | DNMTs | chemosensitizer | vesicle | inhibit | antiepileptic | Temozolomide | DNA Methyltransferase | HDA | Inhibitor | Levetiracetam | SV2A | UCB L-059 | synaptic | protein | DNA MTases | MGMT | UCB L 059 | glioblastoma | apoptosis |
| Inhibitors Related | Nisoldipine | Nimodipine | 2,5-Di-tert-butylhydroquinone | Diltiazem hydrochloride | L-Ascorbic acid | Lanthanum(III) chloride heptahydrate | Ethyl cinnamate | 1-Octanol | γ-Oryzanol | 2-Nitrobenzoic acid | Methyl homoveratrate | Otilonium bromide |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Active Compound Library |
United States
